As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Drs. Summergrad and Insel reflect on the progress and remaining questions in psychedelic science since 2017. They delve into topics like efficacy, regulation, therapy, and provider experience.
Paul Summergrad, Tom Insel, Rachel Nuwer
Psygen and Filament Health, Canadian psychedelic companies, discuss the transformative potential of psychedelics for mental health, addressing manufacturing challenges and the development of standardized natural psychedelic medicines.
Benjamin Lightburn, Daniel “Danny” Motyka
Panel discusses LGBT+ perspectives on psychedelic therapy, emphasizing community's healing role. Recommendations for queer-inclusive therapy and research draw from queer history, including AIDS crisis and conversion therapy.
Alex Belser, Clancy Cavnar
Psychedelic Science 2023 features opening land acknowledgement and addresses by Rick Doblin, Governor Rick Perry, and Governor Jared Polis.
Gov. Rick Perry, Governor Jared Polis, Maya Padilla
Dr. Fadiman shares insights from personal psychedelic experiences and interactions with key pioneers, highlighting how psychedelics influence his Integrative Medicine philosophy and potential for global impact.
Andrew Weil
Discussion between experts on pragmatic frameworks, demographic considerations, and evidence-based practices shaping psychedelic policy reform for diverse contexts, addressing regulatory challenges and fostering nuanced understanding.
Tatiana Quintana, Melissa Lavasani, Logan Davidson
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Hardman provides a quick overview of the emerging psychedelic sector, covering financial, research, and policy landscapes with data visuals. He also explores unanswered questions about the sector's future.
Josh Hardman
NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study
Joshua A Gordon